Antares Pharma (ATRS) is being set up to run to at least $3.85, Thesis follows below; The chart above shows “quiet” accumulation. The purple line is the accumulation, notice for the first time, the accumulation points up, MACD and RSI…
Aveo Chart Technicals
I see a strong chart set up from above. We see a nice continuation pattern, super strong accumulation and RSI, both showing a cup and handle type pattern.Therefore, my short term trade target opinion is $8.25 Aveo has an…
Valeant Acquires Obagi, Which Biotechs Are Next?
Yesterday, Obagi Medical Products (OMPI) was acquired by Valeant Pharmaceuticals (VRX) for $19.75 a share in an all cash deal. Last summer I covered in depth, acquisition rumors regarding Obagi. At the time, good private sources of mine confirmed that…
Significant catalysts and an unfortunate PR mistake present an opportunity in AcelRx Pharmaceuticals.
With The positive result of the first phase III study, coupled with the positive responses of nurses and patients, AcelRx Pharmaceuticals (ACRX) saw a substantial increase in its share price, reaching a high of $5.19 in late November. As is often…
AcelRx Pharma Selloff Caused By Error In Recent Press Release
On March 12th, Acelrx (ACRX) released a pr covering its last quarter’s earnings. In the pr, the company stated that it had cash to last only to Q3 of this year. However, in the official conference call minutes, the company…
$ACRX Trade Call – Target $5.75
$ACRX Trade Call – Target $5.75 Accumulation, MACD and RSI are trending upwards per the 3 day 10 minute chart above. Lots of good things ahead for ACRX. I think my $5.75 target is low like it was for $TSRX…
Download $TSRX Analyst Report
Download Analyst Report on $TSRX HERE-TSRX-SunTrust-Robinson-Humphrey-Feb-12
$TSRX trade call target = $6 + data coming, more DD to follow
Trius Therapeutics (TSRX) I bought $TSRX trade call target = $6 + Trius is expecting top-line data from its 2nd Phase III trial of Tedizolid (TR-701) vs. Linezolid for the treatment of acute bacterial skin and skin structure infections (ABSSSI)…
Why the latest rally could be a bull trap
This week has been a strange market week for sure. I have held back on picks mainly because I want to see some clarity as I believe we are at a market top, and economic data has peaked out. Furthermore,…
GLOBE NEWSWIRE: Pluristem Receives FDA Orphan Drug Status Designation for Treatment of Aplastic Anemia
HAIFA, Israel, Feb. 21, 2013 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the U.S. Food and Drug Administration (FDA) has designated Pluristem’s PLacental eXpanded (PLX) cells orphan drug status…
